Muhimbili University of Health and Allied Sciences
Institutional Repository

Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study

Show simple item record

dc.contributor.author Kilewo, C.
dc.contributor.author Karlsson, K.
dc.contributor.author Ngarina, M.
dc.contributor.author Massawe, A.
dc.contributor.author Lyamuya, E.
dc.contributor.author Swai, A.
dc.contributor.author Lipyoga, R.
dc.contributor.author Mhalu, F.
dc.contributor.author Biberfeld, G.
dc.date.accessioned 2013-02-12T08:29:06Z
dc.date.available 2013-02-12T08:29:06Z
dc.date.issued 2009
dc.identifier.citation Kilewo, C., Karlsson, K., Ngarina, M., Massawe, A., Lyamuya, E., Swai, A., ... & Biberfeld, G. (2009). Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(3), 406-416.
dc.identifier.issn 0b013e3181b323ff.
dc.identifier.uri http://hdl.handle.net/123456789/320
dc.description.abstract Objective: The main aim of this study was to reduce breast-milk transmission of HIV-1 by treating HIV-1–infected women with highly active antiretroviral therapy (HAART) during breastfeeding. Methods: Mitra Plus was an open-label, nonrandomized, prospective cohort study. HIV-1–infected pregnant women in Dar es Salaam were treated with zidovudine (ZDV) + lamivudine (3TC) + nevirapine (NVP). NVP was later replaced by nelfinavir for mothers with CD4 cell counts .200 cells per microliter or with adverse reaction to NVP. HAARTwas initiated at 34 weeks of gestation. For women with symptomatic HIV infection or CD4 cell counts below 200 cells per microliter, HAART was started earlier if possible. Treatment of the mothers was stopped at 6 months except for those mothers who needed HAART for their own health. The infants received ZDV + 3TC for 1 week after birth. Mothers were advised to exclusively breastfeed and to wean abruptly between 5 and 6 months. Transmission of HIV-1 was analyzed using the Kaplan–Meier survival technique. Cox regression was used for comparison with the breastfeeding population of the Petra trial arm A. Results: There were 441 infants included in the analysis of HIV-1 transmission. The cumulative transmission of HIV-1 was 4.1 % [95% confidence interval (CI): 2.2 to 6.0] at 6 weeks, 5.0% (95% CI: 2.9to 7.1) at 6 months, and 6.0% (95% CI: 3.7 to 8.3) at 18 months after delivery. The cumulative risk of HIV transmission between 6 weeks and 6 months was 1.0% and between 6 months and 18 months 1.1%. The cumulative HIV infection or death rate was 8.6% (95% CI: 6.0 to 11.2) at 6 months and 13.6% (95% CI: 10.3 to 16.9) at 18 months after delivery. Viral load at enrollment and duration of HAART before delivery were significantly associated with transmission but CD4 cell count at enrollment was not. The median time of breastfeeding was 24 weeks. The transmission in the Mitra Plus study was about half of the transmission in the breastfeeding population in the Petra trial arm A at 6 months after delivery (adjusted relative hazard = 0.49, P , 0.001). The combined outcome HIV infection or death was significantly lower in the Mitra Plus study than in the breastfeeding population in the Petra trial arm A at 18 months (adjusted relative hazard = 0.61, P = 0.007). NVP-related mucocutaneous rash was demonstrated in 6.5% of 429 NVP-exposed women. The incidence of NVP-related grade 3 or 4 hepatotoxicity was low (0.5%). Conclusions: HAART given to HIV-infected mothers in late pregnancy and during breastfeeding resulted in a low postnatal HIV transmission similar to that previously demonstrated in the Mitra study in Dar es Salaam using infant prophylaxis with 3TC during breastfeeding. The extended maternal prophylaxis with HAART for prevention of mother-to-child transmission of HIV-1 for breastfeeding mothers who do not need HAART for their own health should be further evaluated and compared with the use of infant postnatal antiretroviral prophylaxis regarding safety and cost-effectiveness. en_GB
dc.language.iso en en_GB
dc.publisher Lippincott Williams & Wilkins en_GB
dc.relation.ispartofseries Acquired Immune Deficiency Syndromes; 52:406–416
dc.subject Africa en_GB
dc.subject antiretroviral treatment en_GB
dc.subject breastfeeding en_GB
dc.subject HIV en_GB
dc.subject mother-to-child transmission en_GB
dc.subject Mitra Plus Study en_GB
dc.subject prevention
dc.title Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study en_GB
dc.type Article en_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MUHAS Repository


Advanced Search MUHAS Repository

Browse

My Account